TGFBI deficiency predisposes mice to spontaneous tumor development

Cancer Research

Volumn 69, Issue 1, 2009, Pages 37-44

  Zhang, Ye ^a,c   Wen, Gengyun ^a   Shao, Genze ^a,d   Wang, Cuidong ^b   Lin, Chyuansheng ^a   Fang, Hongbo ^c   Balajee, Adayabalam S ^a   Bhagat, Govind ^a   Hei, Tom K ^a   Zhao, Yongliang ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D1; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; DISEASE MODEL; FEMALE; FIBROBLAST; GENE DISRUPTION; GENE FREQUENCY; GENE LOCUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRONUCLEUS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN SECRETION; SKIN TUMOR; TGFB1 GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CHROMOSOME ABERRATIONS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN D1; FEMALE; G1 PHASE; GENES, BCL-1; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; S PHASE; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 58249113822     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1648     Document Type: Article

References (47)

1. Tlsty TD. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol 1998;10:647-53.
2. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
3. Danen EH. Integrins: regulators of tissue function and cancer progression. Curr Pharm Des 2005;11:881-91.
4. Ramsay AG, Marshall JF, Hart IR. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev 2007;26:567-78.
5. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of β ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-β. DNA Cell Biol 1992;11:511-22.
6. LeBaron RG, Bezverkov KI, Zimber MP, Pavelec R, Skonier J, Purchio AF. β IG-H3, a novel secretory protein inducible by transforming growth factor-β, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. J Invest Dermatol 1995;104:844-9.
7. Billings PC, Herrick DJ, Kucich U, et al. Extracellular matrix and nuclear localization of β ig-h3 in human bladder smooth muscle and fibroblast cells. J Cell Biochem 2000;79:261-73.
8. Kim JE, Jeong HW, Nam JO, et al. Identification of motifs in the fasciclin domains of the transforming growth factor-β-induced matrix protein βig-h3 that interact with the αvβ5 integrin. J Biol Chem 2002;277:46159-65.
9. Nam JO, Kim JE, Jeong HW, et al. Identification of the αvβ3 integrin-interacting motif of βig-h3 and its antiangiogenic effect. J Biol Chem 2003;278:25902-9.
10. Jeong HW, Kim IS. TGF-β1 enhances βig-h3-mediated keratinocyte cell migration through the α3β1 integrin and PI3K. J Cell Biochem 2004;92:770-80.
11. Genini M, Schwalbe P, Scholl FA, Schafer BW. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 1996;66:571-7.
12. Zhao YL, Piao CQ, Hei TK. Downregulation of βig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 2002;2:7471-7.
13. Zhao Y, El-Gabry M, Hei TK. Loss of βig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog 2006;45:84-92.
14. Calaf G, Echiburu-Chau C, Zhao YL, Hei TK. Bigh3 protein expression as a marker for breast cancer. Int J Mol Med 2008;21:561-8.
15. Shao G, Berenguer J, Borczuk AC, Powell CA, Hei TK, Zhao Y. Epigenetic inactivation of βig-h3 gene in human cancer cells. Cancer Res 2006;66:4566-73.
16. Thapa N, Lee BH, Kim IS. TGFBIp/βig-h3 protein: a versatile matrix molecule induced by TGF-β. Int J Biochem Cell Biol 2007;39:2183-94.
17. Ahmed AA, Mills AD, Ibrahim AE, et al. The extracellular matrix protein induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 2007;12:514-27.
18. Nam JO, Jeong HW, Lee BH, Park RW, Kim IS. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of βig-h3, via αvβ3 integrin. Cancer Res 2005;65:4153-61.
19. Becker J, Volland S, Noskova I, Schramm A, Schweigerer LL, Wilting J. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion. Int J Oncol 2008;32:235-40.
20. Kuo MH, Allis CD. In vivo cross-linking and immunoprecipitation for studying dynamic protein:DNA associations in a chromatin environment. Methods 1999;19:425-33.
21. Li ZY, Yang J, Gao X, et al. Sequential recruitment of PCAF and BRG1 contributes to myogenin activation in 12-O-tetradecanoylphorbol-13- acetate-induced early differentiation of rhabdomyosarcoma-derived cells. J Biol Chem 2007;282:18872-8.
22. Zijlmans JM, Martens UM, Poon SS, et al. Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. Proc Natl Acad Sci U S A 1997;94:7423-8.
23. Eto I. Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester-induced tumour promotion. Cell Prolif 2000;33:167-87.
24. Peralta RC, Casson AG, Wang RN, Keshavjee S, Redston M, Bapat B. Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer. Int J Cancer 1998;78:600-5.
25. Wu X, Zhao Y, Kemp BL, Amos CI, Siciliano MJ, Spitz MR. Chromosome 5 aberrations and genetic predisposition to lung cancer. Int J Cancer 1998;79:490-3.
26. Brezinova J, Zemanova Z, Cermak J, Michalova K. Fluorescence in situ hybridization confirmation of 5q deletions in patients with hematological malignancies. Cancer Genet Cytogenet 2000;117:45-9.
27. Assoian RK. Anchorage-dependent cell cycle progression. J Cell Biol 1997;136:1-4.
28. 1-phase progression. Genes Dev 1999;13:1501-12.
29. 1 phase cell cycle progression. Cancer Metastasis Rev 2005;24:383-93.
30. 1 cell cycle regulation. Breast Cancer Res Treat 2004;84:33-42.
31. Hunter T, Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
32. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
33. Robles AI, Rodriguez-Puebla ML, Glick AB, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998;12:2469-74.
34. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
35. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999;68:821-61.
36. Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X, Bertherat J. Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann N Y Acad Sci 2002;968:65-74.
37. Shankar DB, Cheng JC, Kinjo K, et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005;7:351-62.
38. Delghandi MP, Johannessen M, Moens U. The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal 2005;17:1343-51.
39. Caravatta L, Sancilio S, di Giacomo V, Rana R, Cataldi A, Di Pietro R. PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL. J Cell Physiol 2008;214:192-200.
40. Jefford CE, Irminger-Finger I. Mechanisms of chromosome instability in cancers. Crit Rev Oncol Hematol 2006;59:1-14.
41. Nowak MA, Komarova NL, Sengupta A, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A 2002;99:16226-31.
42. Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 2007;7:911-24.
43. Schneider D, Kleeff J, Berberat PO, et al. Induction and expression of βig-h3 in pancreatic cancer cells. Biochim Biophys Acta 2002;1588:1-6. 1.
44. Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, Lerman MI. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun 2008;370:536-40.
45. Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008;22:308-21.
46. Kannabiran C, Klintworth GK. TGFBI gene mutations in corneal dystrophies. Hum Mutat 2006;27:615-25.
47. Bustamante M, Tasinato A, Maurer F, et al. Overexpression of a mutant form of TGFBI/BIGH3 induces retinal degeneration in transgenic mice. Mol Vis 2008;14:1129-37.